The drugs are Pfizer’s Corvert and vincristine sulfate injection.
Corvert is an anti-arrhythmic heart drug used to treat atrial fibrillation or atrial flutter. Vincristine is a chemotherapy drug, used mostly in childhood cancers.
Both drugs are currently facing shortages, so ProvideGx and Pfizer’s partnership aims to create a long-term supply of the two drugs for hospitals.
ProvideGx said it has a list of more than 50 other drugs currently in shortage it plans to supply in the future.
The financial details of ProvideGx and Pfizer’s partnership weren’t disclosed.
Read the full news release here.
More articles on pharmacy:
21 states reject $18B opioid settlement offer from McKesson, Cardinal, AmerisourceBergen
BCBS responds to physician pushback on mail-order pharmacy plan
The 20 most expensive drugs in the US in 2020
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.